Humana Just Got a Massive Upgrade From Deutsche Bank: Price Target Nearly Doubles to $441

Deutsche Bank just delivered one of the most aggressive analyst upgrades of 2026 on Humana (NYSE:HUM | HUM Price Prediction), lifting the managed care giant to Buy from Hold while nearly doubling its price target to $441 from $235. The move signals that one of Wall Street’s more cautious voices now sees a fundamental reset in the Humana franchise.

Adding to the bullish chorus, Mizuho raised its Humana price target to $335 from $290 and kept an Outperform rating, citing a reduced likelihood of negative medical loss ratio shifts through 2026. For prudent investors weighing a healthcare rebound trade, the upgrade reframes Humana stock as a recovery story rather than a falling knife.

The Analyst’s Case

Deutsche Bank’s thesis rests on a stabilizing managed care market and an expectation that Humana’s Medicare star ratings will recover. Star ratings drive bonus payments, premium positioning, and enrollee plan selection during Annual Election Period shopping.

The firm also frames 2026 as the earnings bottom and a rebasing year, depending on the stars results in October. With Humana having already affirmed FY2026 adjusted EPS of at least $9 against the prior year’s $17.14, the reset narrative has data behind it.

Company Snapshot

Humana is a Louisville-based managed care leader anchored by Individual Medicare Advantage, CenterWell Primary Care, and CenterWell Pharmacy Solutions. Q1 2026 results beat on both lines, with adjusted EPS of $10.31 on revenue of $39.65 billion, up 24% year over year.

Individual Medicare Advantage membership climbed 22% year to date, and the insurance segment benefit ratio came in at 89%, slightly favorable to guidance. Humana CEO Jim Rechtin noted, “We’ve had a solid start to the year and feel good about how our operating execution and transformation initiatives are setting us up for the future.”

Why the Move Matters Now

HUM stock has staged a sharp comeback, rising 51% over the past month through May 19 and 22% year to date. Deutsche Bank’s upgrade serves as sell-side validation of that rally, particularly given the prior consensus average target of $246.83.

At a P/E ratio of 33x on trailing earnings and a forward P/E ratio of 30x, Humana stock isn’t cheap on near-term numbers. The Deutsche Bank call argues that depressed 2026 earnings normalize materially higher as stars and rates improve.

What It Means for Your Portfolio

The bull case is straightforward: star ratings recovery, a friendlier Medicare Advantage rate cycle, completed valuation rebase, and dominant MA exposure that gives Humana upside leverage as conditions improve. The Mizuho raise reinforces that the operating backdrop is stabilizing.

However, the risks remain real. October’s stars results are still a binary catalyst, MA reimbursement remains politically sensitive, and a securities fraud lawsuit tied to Medicare Advantage utilization disclosures was partially allowed to proceed on May 19.

For long-term investors, Humana stock now sits at the intersection of a credible recovery thesis and a stock that has already moved sharply. Sizing positions modestly and watching for whether October’s star ratings confirm the Deutsche Bank thesis could be the more prudent path than chasing the upgrade.